EC approves RoActemra label expansion for the treatment of early RA

• The European Commission approves Roche's (OTCQX:RHHBY) RoActemra (tocilizumab) for the treatment of patients with severe, active and progressive rheumatoid arthritis (RA) who have not been treated with methotrexate. It is the first interleukin-6 (IL-6) receptor antagonist approved in Europe for early RA.
• The early RA indication is the fifth update and expansion to RoActemra's European label in three years.